Healthy Men Clinical Trial
Official title:
Gender Differences in Social Cognition in Patients With Schizophrenia of Recent Diagnosis and Healthy Controls Subjects
Verified date | January 2018 |
Source | Corporacion Parc Tauli |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Individuals with schizophrenia have important and persistent deficits in multiple
neurocognitive domains as well as in the Social Cognition (SC). SC refers to the mental
operations underlying social behavior, and it is understood as a multidimensional construct
that comprises emotional processing (EP), social perspective and knowledge, attributional
bias and theory of mind (ToM) or mentalizing. Mentalizing and EP skills have been the two
most studied subdomains of SC in schizophrenia. Both domains have been found to be impaired
in chronic schizophrenia patients as well as in patients in early stages of the illness. In
this context, although negative symptoms may play and important role, females seem to perform
better than males in ToM and EP tasks, suggesting the presence of gender differences in the
SC skills in patients with schizophrenia. However, to our knowledge, there are no studies
that have explored the gender-related differences between cognitive and affective ToM and its
relationship with the EP performance in schizophrenia patients of recent diagnosis comparing
with healthy subjects.
In this line, the main objective of this project is to analyze the influence of gender in the
cognitive and affective ToM abilities, in a group of patients with schizophrenia in early
stages of the illness comparing with healthy subjects. Secondarily, this study pretends to
explore the association between EP skills and affective ToM tasks performance in males and
females with and without recent diagnosis of schizophrenia.
Status | Completed |
Enrollment | 80 |
Est. completion date | July 2016 |
Est. primary completion date | July 2016 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 45 Years |
Eligibility |
PARTICIPANTS WITH SCHIZOPHRENIA Inclusion Criteria: - Patients meeting DSM-IV criteria for schizophrenia or schizoaffective disorder with less than 5 years of evolution of the disorder. - Being an outpatient for at least 4 weeks before the study (clinical stability). - No changes in the antipsychotic medication during the month before the study. - Score less than 4 in the P1, P2 and P3 items of the PANSS. - Score less than 4 in the Calgary Depression Scale. Exclusion Criteria: - Intellectual disability (IQ<70). - History of brain damage. - History of substance abuse (except nicotine or caffeine) during the last 12 months before the study. PARTICIPANTS WITHOUT SCHIZOPHRENIA Inclusion Criteria: • Healthy people over 18 years old. Exclusion Criteria: - Sensory impairment: visual or hearing disabilities. - Intellectual disability (IQ<70). - History of neurologic disease. - History of psychiatric disorder. - History of substance abuse (except nicotine or caffeine) during the last 12 months before the study. |
Country | Name | City | State |
---|---|---|---|
Spain | Corporació Parc Taulí | Sabadell | Barcelona |
Lead Sponsor | Collaborator |
---|---|
Corporacion Parc Tauli |
Spain,
Abu-Akel A, Bo S. Superior mentalizing abilities of female patients with schizophrenia. Psychiatry Res. 2013 Dec 30;210(3):794-9. doi: 10.1016/j.psychres.2013.09.013. Epub 2013 Oct 5. — View Citation
Bora E, Pantelis C. Theory of mind impairments in first-episode psychosis, individuals at ultra-high risk for psychosis and in first-degree relatives of schizophrenia: systematic review and meta-analysis. Schizophr Res. 2013 Mar;144(1-3):31-6. doi: 10.1016/j.schres.2012.12.013. Epub 2013 Jan 21. Review. — View Citation
Bozikas VP, Andreou C. Longitudinal studies of cognition in first episode psychosis: a systematic review of the literature. Aust N Z J Psychiatry. 2011 Feb;45(2):93-108. doi: 10.3109/00048674.2010.541418. Review. — View Citation
Green MF, Penn DL, Bentall R, Carpenter WT, Gaebel W, Gur RC, Kring AM, Park S, Silverstein SM, Heinssen R. Social cognition in schizophrenia: an NIMH workshop on definitions, assessment, and research opportunities. Schizophr Bull. 2008 Nov;34(6):1211-20. doi: 10.1093/schbul/sbm145. Epub 2008 Jan 8. — View Citation
Kohler CG, Turner TH, Bilker WB, Brensinger CM, Siegel SJ, Kanes SJ, Gur RE, Gur RC. Facial emotion recognition in schizophrenia: intensity effects and error pattern. Am J Psychiatry. 2003 Oct;160(10):1768-74. — View Citation
Mesholam-Gately RI, Giuliano AJ, Goff KP, Faraone SV, Seidman LJ. Neurocognition in first-episode schizophrenia: a meta-analytic review. Neuropsychology. 2009 May;23(3):315-36. doi: 10.1037/a0014708. Review. — View Citation
Savla GN, Vella L, Armstrong CC, Penn DL, Twamley EW. Deficits in domains of social cognition in schizophrenia: a meta-analysis of the empirical evidence. Schizophr Bull. 2013 Sep;39(5):979-92. doi: 10.1093/schbul/sbs080. Epub 2012 Sep 4. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Intelligence Quotient (IQ) in schizophrenia groups | Measured by: The abbreviated form of the Wechsler Adult Intelligence Scale (WAIS-III) (Blyder et al., 2000) | Through study completion, an average of 6 months | |
Other | Intelligence Quotient (IQ) in healthy groups | Measured by: The Vocabulary subtest (WAIS-III) in healthy participants. | Through study completion, an average of 6 months | |
Primary | Affective Theory of Mind | Measured by: Reading the Mind in the Eyes test (RMET) | Through study completion, an average of 6 months | |
Primary | Cognitive Theory of Mind | Measured by: False belief stories | Through study completion, an average of 6 months | |
Secondary | Emotional Processing | Measured by: Pictures of Facial Affect (POFA) | Through study completion, an average of 6 months | |
Secondary | Psychosis Symptoms | Measured by: Positive and Negative Syndrome Scale | Through study completion, an average of 6 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00900107 -
Time-Dependent Mobilization of Circulating Progenitor Cells During Strenuous Exercise in Healthy Individuals
|
N/A | |
Completed |
NCT02517775 -
Effects of Cranberry Consumption in Vascular Function in Healthy Individuals
|
N/A | |
Active, not recruiting |
NCT03298373 -
28-Day Repeat-Dose, Dose Escalation Study of 11-β Methyl Nortestosterone Dodecylcarbonate (11β-MNTDC) in Healthy Men
|
Phase 1 | |
Completed |
NCT03339167 -
Metabolic Availability of Lysine From Millet in Adult Men
|
N/A | |
Completed |
NCT01710280 -
Palmitic Acid in the Sn-2 Position of Triacylglycerols and Postprandial Lipemia
|
N/A | |
Completed |
NCT01130948 -
Sleep, Breathing and Psychomotor Performance at Altitude: A Physiologic Study in Healthy Subjects
|
N/A | |
Completed |
NCT01382069 -
Phase 1 Study of Dimethandrolone Undecanoate in Healthy Men
|
Phase 1 | |
Recruiting |
NCT05523674 -
Effects of Warm-up Intensity and Blood Flow Restriction
|
N/A | |
Not yet recruiting |
NCT05865574 -
A Comparative Pharmacokinetic Study to Evaluate Different Manufacturing Batches of BAT1706 Injection
|
Phase 1 | |
Completed |
NCT01293591 -
Garlic Intake And Biomarkers Of Cancer Risk
|
N/A | |
Completed |
NCT01296997 -
Calcium Phosphate and Incretins
|
N/A | |
Completed |
NCT01221558 -
Effects of Lycopene on Oxidative Stress and Markers of Endothelial Function Healthy Men
|
Phase 3 | |
Completed |
NCT00935662 -
A First Time in Man, Study to Assess the Safety of AZD8329 After Single Ascending Oral Doses
|
Phase 1 | |
Active, not recruiting |
NCT05825781 -
Study, Evaluating Pharmacokinetics, Immunogenicity and Safety Profiles of Pertuzumab Compared to Perjeta® in Healthy Man
|
Phase 1 | |
Completed |
NCT02994602 -
Study of Serum Testosterone and Nestorone in Females After Secondary Exposure to Nestorone ® (NES) + Testosterone (T) Combined Gel Applied to Shoulders and Upper Arms in Males
|
Phase 1 | |
Completed |
NCT02365987 -
The Acute Effects of Interesterification of Commercially Used Fats on Postprandial Lipaemia and Satiety
|
N/A | |
Completed |
NCT02093169 -
D2 Dopamine Receptor Occupancy After Oral Dosing of Lu AF35700 in Healthy Men Using [11C]-PHNO as Tracer Compound
|
Phase 1 | |
Completed |
NCT02072278 -
Electroencephalography Study Investigating the Effects of Vortioxetine in Healthy Male Subjects
|
Phase 1 | |
Completed |
NCT03411005 -
Metabolic Availability of Lysine From Sorghum in Adult Men
|
N/A | |
Recruiting |
NCT02927210 -
Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)
|
Phase 1 |